What Patients Should Know About Ozempic and Gastroparesis

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

General Health and Science Information Legacy

If you take Ozempic and have noticed persistent nausea, vomiting, or abdominal pain, you may be wondering if the medication could be linked to gastroparesis. The long-standing tradition of medical education has helped patients and clinicians navigate such complex side effects. This page outlines the key facts about diagnosis and monitoring for Ozempic-associated gastroparesis.

Clinical Presentation and Pharmacological Profile

Ozempic, a glucagon-like peptide-1 (GLP-1) receptor agonist, is prescribed for glycemic control in type 2 diabetes. However, its use has been associated with significant gastrointestinal adverse effects, including gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction. This narrative examines the clinical presentation of gastroparesis, the pharmacological profile of Ozempic, reported adverse effects, mechanistic pathways linking the drug to gastroparesis, adequacy of warnings, settlement considerations for affected patients, and the timeline between exposure and documented harm. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can lead to malnutrition, dehydration, and impaired quality of life. In the context of Ozempic use, these symptoms may overlap with common gastrointestinal reactions reported in clinical trials. The pharmacology of Ozempic involves activation of GLP-1 receptors, which slows gastric emptying as part of its mechanism to reduce postprandial glucose excursions. This effect is dose-dependent and can become pathological in susceptible individuals.

Reported Adverse Effects and Mechanistic Pathways

Clinical trial data indicate that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 32.7% with Ozempic 0.5 mg, 36.4% with Ozempic 1 mg, and 34.0% with Ozempic 2 mg, compared to 15.3% with placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and discontinuation rates due to gastrointestinal adverse reactions were 3.1% for Ozempic 0.5 mg and 3.8% for Ozempic 1 mg, versus 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, specific gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (3.5% with 0.5 mg, 2.7% with 1 mg), gastroesophageal reflux disease (1.9% with 0.5 mg, 1.5% with 1 mg), and gastritis (0.8% with 0.5 mg, 0.4% with 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these figures do not explicitly list gastroparesis, the symptoms and mechanisms align with the condition. Mechanistically, Ozempic delays gastric emptying by inhibiting vagal nerve activity and relaxing the gastric fundus, which can lead to prolonged retention of gastric contents. In some patients, this effect may persist beyond the intended therapeutic window, resulting in gastroparesis. The drug's long half-life (approximately one week) means that even after discontinuation, its effects on gastric motility may continue for several weeks. This delayed clearance can exacerbate symptoms and complicate recovery.

Adequacy of Warnings and Settlement Considerations

Regarding the adequacy of warnings, the prescribing information for Ozempic includes a section on gastrointestinal adverse reactions but does not specifically mention gastroparesis as a distinct warning. The label notes that serious hypersensitivity reactions have been reported, including anaphylaxis and angioedema, and advises caution in patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may leave patients and healthcare providers unaware of this potential risk. This gap in labeling could be relevant in legal contexts, as patients who develop gastroparesis after using Ozempic may argue that the manufacturer failed to provide adequate warnings. Settlement-related considerations for affected patients in California involve several factors. First, the plaintiff must establish that Ozempic caused their gastroparesis, which requires medical evidence linking the drug to the condition. Second, the timeline between exposure and documented harm is critical. Clinical trials show that gastrointestinal adverse reactions often occur during dose escalation, but gastroparesis may develop after prolonged use or even after discontinuation due to the drug's long half-life. Patients who experience persistent symptoms after stopping Ozempic may have a stronger case, as the harm is clearly associated with the drug. Third, the severity of the condition—such as hospitalization, need for feeding tubes, or long-term disability—can influence settlement amounts. California courts may consider the adequacy of warnings, the manufacturer's knowledge of the risk, and whether the patient was informed of alternative treatments. In summary, Ozempic use is associated with a range of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The drug's mechanism of delaying gastric emptying, combined with its long half-life, creates a plausible pathway for the development of this condition. The current labeling does not specifically warn about gastroparesis, which may be a point of contention in legal claims. Patients in California who have suffered from gastroparesis after using Ozempic should consult with a medical professional and an attorney to evaluate their case, considering the timeline of exposure and the adequacy of warnings provided.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it related to Ozempic?

Gastroparesis is a condition characterized by delayed gastric emptying without mechanical obstruction, leading to symptoms like nausea, vomiting, early satiety, and abdominal pain. Ozempic, a GLP-1 receptor agonist, slows gastric emptying as part of its mechanism, which can become pathological in some patients, potentially causing gastroparesis. Clinical trial data show higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does the Ozempic label specifically warn about gastroparesis?

No, the prescribing information for Ozempic does not specifically mention gastroparesis as a distinct warning. It includes a section on gastrointestinal adverse reactions but does not list gastroparesis. This absence may be relevant in legal claims regarding inadequate warnings (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What should I do if I developed gastroparesis after taking Ozempic in California?

If you developed gastroparesis after using Ozempic, you should consult with a medical professional for diagnosis and treatment, and consider speaking with an attorney experienced in pharmaceutical injury claims. Key factors include establishing causation, documenting the timeline of exposure and symptoms, and assessing the adequacy of warnings provided by the manufacturer.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.